down arrow

Avrobio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US05455M1009
USD
21.41
1.85 (9.46%)

Dec 22

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

19.7521.51

52 Week

13.7061.07
Valuation
Technical
Day's Volume

CASH

66.82 k

Shareholding (Mar 2025)

FII

2.61%

Held by 35 FIIs

DII

71.2%

Held by 18 DIIs

Promoter

9.49%

How big is Avrobio, Inc.?

22-Jun-2025

As of Jun 18, Avrobio, Inc. has a market capitalization of 378.25 million, with net sales of 0.00 million and a net profit of -58.67 million over the latest four quarters. As of Dec'24, shareholder's funds were 140.78 million and total assets were 152.91 million.

Market Cap: As of Jun 18, Avrobio, Inc. has a market capitalization of 378.25 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Avrobio, Inc. reported net sales of 0.00 million and a net profit of -58.67 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 140.78 million, while total assets were reported at 152.91 million.

Read More

What does Avrobio, Inc. do?

22-Jun-2025

Avrobio, Inc. is a clinical-stage gene therapy company developing ex vivo lentiviral-based therapies for rare diseases, with a market cap of $378.25 million and a recent net profit of -$16 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.

Overview: <BR>Avrobio, Inc. is a clinical-stage gene therapy company focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 378.25 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -18.98% <BR>Price to Book: 1.26<BR><BR>Contact Details: <BR>Address: 1 Kendall Sq Bldg 300 Ste 201, CAMBRIDGE MA: 02139-1562 <BR>Tel: ['1 781 9626030', '1 339 9702843'] <BR>Fax: 1 302 6365454 <BR>Website: http://www.avrobio.com

Read More

Who are in the management team of Avrobio, Inc.?

22-Jun-2025

As of March 2022, the management team of Avrobio, Inc. includes Dr. Bruce Booth (Independent Chairman), Mr. Geoff MacKay (President and CEO), and several independent directors: Dr. Gail Farfel, Mr. Ian Clark, Mr. Phillip Donenberg, Dr. Annalisa Jenkins, and Dr. Christopher Paige. This team provides leadership and strategic direction for the company.

As of March 2022, the management team of Avrobio, Inc. includes the following individuals:<BR><BR>- Dr. Bruce Booth, who serves as the Independent Chairman of the Board.<BR>- Mr. Geoff MacKay, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Gail Farfel, who is a Director.<BR>- Mr. Ian Clark, who is an Independent Director.<BR>- Mr. Phillip Donenberg, who is also an Independent Director.<BR>- Dr. Annalisa Jenkins, who serves as an Independent Director.<BR>- Dr. Christopher Paige, who is an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Avrobio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Avrobio, Inc. is in a bearish trend with strong technical indicators supporting this view, including bearish MACD and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -66.13%.

As of 3 September 2025, the technical trend for Avrobio, Inc. has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bearish trend. Daily moving averages confirm the bearish outlook. The KST is bearish weekly and mildly bearish monthly, while the Dow Theory shows a mildly bearish weekly stance but mildly bullish monthly. The OBV presents a mixed view with mildly bullish weekly and mildly bearish monthly signals.<BR><BR>In terms of performance, Avrobio has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -66.13% compared to the S&P 500's 12.22%, and a 1-year return of -17.68% versus 17.14%. Overall, the technical indicators collectively point to a bearish sentiment for the stock.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 474 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-23.25%

stock-summary
Price to Book

1.67

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
35.68%
0%
35.68%
6 Months
8.08%
0%
8.08%
1 Year
-54.87%
0%
-54.87%
2 Years
32.16%
0%
32.16%
3 Years
2633.31%
0%
2633.31%
4 Years
-53.29%
0%
-53.29%
5 Years
-87.9%
0%
-87.9%

Avrobio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
4.29%
EBIT to Interest (avg)
-79.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
75.51%
ROCE (avg)
0
ROE (avg)
7.29%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.41
EV to EBIT
-1.92
EV to EBITDA
-1.96
EV to Capital Employed
-42.43
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-18.98%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 10 Schemes (16.7%)

Foreign Institutions

Held by 35 Foreign Institutions (2.61%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -57.48% vs -118.81% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.00",
          "val2": "-11.20",
          "chgp": "-96.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.00",
          "val2": "-12.70",
          "chgp": "-57.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -35.51% vs 59.58% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-56.40",
          "val2": "-43.20",
          "chgp": "-30.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.60",
          "val2": "1.00",
          "chgp": "-460.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-58.00",
          "val2": "-42.80",
          "chgp": "-35.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-22.00
-11.20
-96.43%
Interest
0.00
0.00
Exceptional Items
0.00
-1.50
100.00%
Consolidate Net Profit
-20.00
-12.70
-57.48%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -57.48% vs -118.81% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-56.40
-43.20
-30.56%
Interest
0.10
0.20
-50.00%
Exceptional Items
-3.60
1.00
-460.00%
Consolidate Net Profit
-58.00
-42.80
-35.51%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -35.51% vs 59.58% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Avrobio, Inc. stock-summary
stock-summary
Avrobio, Inc.
Pharmaceuticals & Biotechnology
AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.
Company Coordinates stock-summary
Company Details
1 Kendall Sq Bldg 300 Ste 201 , CAMBRIDGE MA : 02139-1562
stock-summary
Tel: 1 781 96260301 339 9702843
stock-summary
http://www.avrobio.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."